The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients
NCT ID: NCT02063607
Last Updated: 2016-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
60 participants
INTERVENTIONAL
2013-12-31
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Peginterferon alfa 2a
Peginterferon alfa 2a 180 mcg
Peginterferon lambda
Peginterferon Lambda
Peginterferon Lambda 60,120,180 and 240 mcg
Peginterferon lambda
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Peginterferon lambda
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Women have a negative pregnancy test result at the time of study.
3. Clinical examination and result laboratory for 7 days before starting the trial must be inside the normal range.
4. Currently not following any treatment regimen (except for using the oral contraceptive).
5. Body mass index is between the range and / or not 25% difference compared to the normal BMI (Appendix 6).
6. Be able to comply with protocol and exchange information effectively with the researchers, agree on the written informed consent to participate in the clinical trial
1. Patients with chronic hepatitis C (male and female).
2. Ages between 18 - 65 years old.
3. Female patient (or female partners of the male patients) with negative pregnancy test results and/or apply effective contraception if still having sex during the study and for 6 months after using the last dose of Ribavirin.
4. No previous treatment with IFN or IFN treatment with rapid viral response or already have completely viral response but leave the treatment early.
5. HCV-RNA levels in serum \> 80 IU / mL.
6. The haematological and biochemical (except ALT / AST) parameters must be within normal limits.
7. Body weight in the normal range of 25% difference compared to the normal BMI (Appendix 6)
8. Be able to comply with protocol and exchange information effectively with the researchers, agree on the written informed consent to participate in the clinical trial
Exclusion Criteria
2. History of depression
3. History of chronic diseases related to the respiratory system, cardiovascular, gastrointestinal, malignant disease affecting to the function of the organ systems. Having any interferon or antiviral therapy within 4 months before the trial
4. Participate in any clinical trial within 3 months prior the testing
5. Use of any drug in the last period of relatively positive test which last approximately 6 times the half-life of the drug.
6. Blood donor with more than 400 mL of blood within 3 months prior the testing
7. Influenza infection or cold symptoms within 2 weeks before the trial
8. Having positive tests of HBV, HCV or HIV
9. Breastfeeding women
1. Co-infection with hepatitis B and/or HIV.
2. Hepatic Impairment
3. Cirrhosis
4. Positive tests with antibody of Peginterferon lambda 1 and Peginterferon alpha 2a.
5. History of chronic diseases related to the respiratory system, cardiovascular, gastrointestinal, malignant disease affecting to the function of the organ systems.
6. A history of immune disorders (eg, inflammatory bowel disease, hemorrhagic thrombocythemia, lupus erythematosus, autoimmune hemolytic anemia, autoimmune disease, scleroderma, severe psoriasis, arthritis rheumatoid ...)
7. A history of severe mental illness, especially depression, especially the serious neurological condition determined as depression or serious psychological disorders, suicidal intention, or being hospitalized for mental illness, or having 1 phase of impaired function due to neuropathy.
8. A history of severe epilepsy or using antiepileptic drugs.
9. A history of using anti-cancer agents (including radiation therapy) or immunotherapy (including systematic corticosteroids) within 6 months before using the first testing dose or the patient may be in need of this treatment during the trial
10. History of organ transplants with the presence of the graft function.
11. Evidence of alcohol or drugs abuse within 1 year before the trial. AUDIT scale - C will be used to assess the use of alcohol. The score ≥ 4 in men or ≥ 3 in women are considered as alcoholics
12. History or evidence of severe disease or any other condition based on the investigator assessment that the subject may not be suitable for this study.
13. Breastfeeding women.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanogen Pharmaceutical Biotechnology Joint Stock Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr.Chinh Trong Nguyen, PhD
Role: PRINCIPAL_INVESTIGATOR
The Military 108 Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Military 108 Hospital
Hanoi, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NNG01
Identifier Type: -
Identifier Source: org_study_id